Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells

Sofer,Gail;

Publication

Article

July 15, 2002

BioPharm International

BioPharm International-07-01-2002

Volume15

Issue 7

Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells

Author(s):

Gail Sofer

by Gail Sofer, BioReliance Viruses present dangers (and therefore challenges) to biopharmaceutical manufacturing processes. The virus inactivation method chosen depends on the virus and its surrounding medium. This survey article, organized by sample type, lists viral inactivation methods published during the past decade. Part 1 presents data for skin and bone and for cells that are not platelets or blood cells.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Facilitating Client Audits: The Contract Laboratory Perspective

Outsourcing Outlook: Optimizing Cross-Organizational Team Performance and Management

Analytical Advances: When an Industry Requires Multiterabyte Data Protection

Validation of Large-Scale Chromatographic Processes, Part 2: Results from the Case Study of Neuleze Capture on Macroprep High-S

Knowledge Management: The Four Pillars of Success

Inside Washington: One Hundred Years of Biotech Regulation

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!